Pfizer reports positive data from Phase 2 study for atopic dermatitis antibody (PFE:NYSE)

NodeGuardian

2026-03-18 03:54:27

Abstract generation in progress

Pfizer announced positive results from its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody developed for atopic dermatitis. The study successfully met its primary endpoint, demonstrating a statistically significant increase in participants achieving at least a 75% reduction in symptoms. This indicates potential for the antibody in treating the condition.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.